Clive R Wood

This inventor holds 37 USPTO granted patents and 12 published patent applications, plus 7 CIPO patents and 6 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Genetics Institute, Inc., Dyax Corporation, Wyeth. Active years: 1998-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clive R Wood. Retrieved from https://idiyas.com/inventor/clive-r-wood

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 12)

% Patents Active = 62.2

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 18

Forward Citations = 1,883(Granted Patents)

Location History:

Cambridge, MA (US) (2009 - 2011)
Boston, MA (US) (1998 - 2016)

Company Filing History:

14 out of 392

Genetics Institute, Inc.

Dana-Farber-Cancer Institute Inc.

Syntonix Pharmaceuticals, Inc.

patents

7. 1 out of 2

Biogen Hemophilia Inc.

patents

8. 1 out of 3,798

Johns Hopkins University

patents

9. 1 out of 1,425

The Brigham and Women's Hospital, Inc.

patents

10. 1 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

11. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2016

Loading Chart...

Areas of Expertise:

PD-1

MMP-14

Antibodies

Immune Response

Cytokine Receptor

Monoclonal Antibodies

Fibrosis Treatment

Nucleic Acids

Cancer Treatment

Therapeutic Methods

Breast Cancer

Patient Stratification

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9260520 - Antibodies to FeRn and uses thereof (2016-02-16),

2. 9051377 - Method for treating breast cancer using antibody binding to MMP-14 (2015-06-09),

3. 8815246 - Fc receptor binding proteins (2014-08-26),

4. 8501181 - Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins (2013-08-06),

5. 8273351 - Fc receptor binding proteins (2012-09-25),

6. 8183008 - Evaluating MMP expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer (2012-05-22),

7. 8147836 - Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins (2012-04-03),

8. 8106168 - Metalloproteinase binding proteins (2012-01-31),

9. 8088905 - Nucleic acids encoding antibodies against PD-1 (2012-01-03),

10. 7871610 - Antibodies to Tie1 ectodomain (2011-01-18),

11. 7745587 - Antibodies that bind MMP-14 (2010-06-29),

12. 7709214 - Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1 (2010-05-04),

13. 7700301 - Methods for screening for compounds that modulate PD-1 signaling (2010-04-20),

14. 7674591 - Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding (2010-03-09),

15. 7638492 - Methods of upmodulating an immune response with non-activating forms of B7-4 (2009-12-29),

Title: The Inventive Journey of Clive R Wood

Introduction:

Clive R Wood is a prolific inventor based in Cambridge, MA (US) who has made significant contributions to the field of biotechnology. With an impressive portfolio of 37 patents, his innovative work has paved the way for advancements in the treatment of various disorders, including autoimmune conditions and breast cancer.

Latest Patents:

Among his latest patents is "Antibodies to FcRn and uses thereof," which details the development of proteins that bind to FcRn, showcasing high affinity and selectivity in inhibiting FcRn. These FcRn-binding proteins hold promise for the treatment of autoimmune disorders. Additionally, Wood's "Method for treating breast cancer using antibody binding to MMP-14" focuses on proteins that bind to matrix metalloproteinase 14, offering novel approaches for combating breast cancer.

Career Highlights:

Throughout his career, Clive R Wood has been associated with renowned companies in the biotechnology sector. He has made notable contributions during his tenure at Genetics Institute, Inc., and Dyax Corporation, where his inventive spirit and dedication to scientific advancement have been instrumental in driving innovation forward.

Collaborations:

Wood has had the privilege of collaborating with esteemed professionals in the industry, including Mary Collins and Debra D Donaldson. These collaborations have led to fruitful partnerships and the exchange of ideas that have further enriched his innovative endeavors.

Conclusion:

Clive R Wood's journey as an inventor exemplifies dedication, ingenuity, and a relentless pursuit of scientific excellence. His groundbreaking patents and collaborations underscore his commitment to pushing the boundaries of biotechnology, ultimately making a difference in the lives of people affected by various medical conditions.

Profile summary based on public USPTO records.